AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34229299
Drug: Core genes
RxNorm normalized name: Genesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core genes involved in regulation of extracellular matrix receptor interaction and chemotactic activity
Trial: 35098820
Drug: High-dose amoxicillin-proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amoxicillin-proton pump inhibitor dual therapy (20 mg esomeprazole four times daily and 750 mg amoxicillin four times daily for 14 days)
Trial: 35098820
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy (220 mg bismuth potassium citrate twice daily, 20 mg esomeprazole twice daily, 1000 mg amoxicillin twice daily, and 250 mg clarithromycin capsule twice daily for 14 days)
Trial: 35098820
Drug: High-dose amoxicillin-proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amoxicillin-proton pump inhibitor dual therapy
Trial: 33902701
Drug: Guided online
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided online cognitive behavioral therapy for insomnia (i-Sleep)
Trial: 33272333
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 international units) administered daily for 5 days
Trial: 33272333
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 international units) administered every other day for 5 days
Trial: 33837458
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression therapy (IPCT) with compression garment (CG) for 45 min, 3 times a week, for 4 weeks.
Trial: 32211803
Drug: HFCM containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFCM containing 6 g spice blend
Trial: 32211803
Drug: HFCM with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFCM with 0 g spice blend
Trial: 34476776
Drug: Control (pseudo-treatment)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (pseudo-treatment)
Trial: 34478870
Drug: Mindfulness-Based Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Therapy (MBT) consisting of eight weekly therapist-led, two-hour group sessions, and home practice (≥30 min/day, 6 days/week) during the 12-month study.
Trial: 33398614
Drug: Photobiomodulation (PBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation (PBM) - transdermal: 980 nm, 200 mW, continuous, average energy fluency of 6 J/cm2 and intravenous: 405 nm, 1.5 mW, continuous for 30 min, applied before and after surgery for 6 days.
Trial: 33970869
Drug: Norgestrel 75
RxNorm normalized name: levonorgestrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestrel 75 mcg taken daily
Trial: 33970869
Drug: Norgestrel 75
RxNorm normalized name: levonorgestrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestrel 75 mcg taken 6 hours late
Trial: 33970869
Drug: Norgestrel 75
RxNorm normalized name: levonorgestrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestrel 75 mcg missed pill
Trial: 35081255
Drug: Salvage chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage chemotherapy (SC)
Trial: 33074192
Drug: Standard-of-care medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care medical therapy (MED)
Trial: 39665575
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for metabolic acidosis
Trial: 33458939
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy with completion of frequency volume charts regularly
Trial: 33132658
Drug: Cap-assisted colonoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cap-assisted colonoscopy (CC) in ulcerative colitis patients
Trial: 33132658
Drug: Cap-assisted colonoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cap-assisted colonoscopy (CC) during unsedated colonoscopy
Trial: 33870426
Drug: G-tube feeding
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-tube feeding
Trial: 38101433
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus platinum-based chemotherapy (group A)
Trial: 38101433
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus platinum-based chemotherapy (group C)
Trial: 32416780
Drug: Atezolizumab monotherapy
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab monotherapy (group B)
Trial: 34874514
Drug: Ubrogepant 50
RxNorm normalized name: ubrogepant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubrogepant 50 mg
Trial: 37937851
Drug: Proton Pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton Pump Inhibitors (PPIs)
Trial: 35524444
Drug: Bumetanide as
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bumetanide as an adjunctive treatment
Trial: 32086915
Drug: Tympanic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tympanic injection of dexamethasone
Trial: 32086915
Drug: Systemic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic administration group
Trial: 35363252
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion
Trial: 36260947
Drug: Premature Infant
RxNorm normalized name: Premature infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premature Infant Oral Motor Intervention (PIOMI) for 5 min/day for 14 days
Trial: 35221304
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg/mL)
Trial: 35221304
Drug: Adrenaline (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline (0.01 mg/mL)
Trial: 32920641
Drug: 5 doses
RxNorm normalized name: diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 doses of 4.5 x 10^5 PfSPZ (Days 1, 3, 5, and 7; Week 16)
Trial: 32920641
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 9.0 × 10^5 PfSPZ (Group 2)
Trial: 32920641
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 18.0 × 10^5 PfSPZ (Group 3)
Trial: 32920641
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 27.0 × 10^5 for dose 1 and 9.0 × 10^5 for doses 2 and 3 (Group 4)
Trial: 33853109
Drug: Post-assessment survey
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-assessment survey regarding willingness to travel for treatment
Trial: 34521217
Drug: Non-insulin-treated diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-insulin-treated diabetes
Trial: 33234944
Drug: Insulin-treated diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-treated diabetes
Trial: 33242251
Drug: Hourly staircase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly staircase sprint interval exercise (stair snacks)
Trial: 38832504
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg thrice daily
Trial: 32576287
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (Paracetamol/Orphenadrine combination)
Trial: 32747473
Drug: Distance learning
RxNorm normalized name: Cistanche tinctoria stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distance learning program consisting of 3 program modules with online tutorials, webinars, booster video vignettes, and individualized antibiotic prescribing feedback reports over 11 months.
Trial: 33051459
Drug: Leptin treatment
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin treatment
Trial: 36443882
Drug: Standard intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine (SP)
Trial: 34100082
Drug: Sequential mixed-nutrient
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential mixed-nutrient meals
Trial: 32489146
Drug: letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: letrozole (2.5 mg daily) and cyclophosphamide (50 mg daily) with Sorafenib (400 mg/bid daily)
Trial: 34880372
Drug: 3% gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% gelatin solution (30 ml/kg) in group A (n=21)
Trial: 34880372
Drug: 3% gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% gelatin solution (15 ml/kg) in group B (n=21)
Trial: 34880372
Drug: Isotonic multi-electrolyte
RxNorm normalized name: MULTI-ELECTROLYTES INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic multi-electrolyte solution in control group C (n=22)
Trial: 35289915
Drug: Full dose-intensity
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose-intensity (DI) in FOLFIRINOX group
Trial: 35289915
Drug: Full dose-intensity
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose-intensity (DI) in FOLFIRI/nab-paclitaxel group
Trial: 35384257
Drug: Topical probiotic-derived
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical probiotic-derived lotion
Trial: 36057827
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once per day
Trial: 35216547
Drug: Leuprorelin (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin (3.75 mg s.c. monthly for the first 3 months followed by 11.25 mg s.c. every 3 months)
Trial: 32692358
Drug: (R)-α-lipoic acid
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-α-lipoic acid (R-LA; 600 mg/d)
Trial: 33231701
Drug: 0.2 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 μg/day fluocinolone acetonide (FAc) intravitreal implant
Trial: 33157330
Drug: Adjunctive photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive photodynamic therapy (aPDT)
Trial: 33157330
Drug: Adjunctive antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive antibiotic gel therapy (aAGT) (metronidazole 400 mg and amoxicillin 500 mg)
Trial: 32928014
Drug: Dexamethasone (2mls,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (2mls, 8 mg) intravenously
Trial: 33382378
Drug: Website and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Website and personalized diet and exercise prescription (level 2)
Trial: 33382378
Drug: Website, personalized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Website, personalized prescription, Fitbit, and text messages (level 3)
Trial: 33382378
Drug: Website, personalized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Website, personalized prescription, Fitbit, text messages, and 2 phone calls (level 4)
Trial: 34418964
Drug: Medication plans
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication plans and discussions with GPs
Trial: 34418964
Drug: Personal experiences
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal experiences with medications
Trial: 35124615
Drug: Digital group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital group (CAD/CAM digital implant guide)
Trial: 33486138
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (active control group, n2 = 20)
Trial: 35267967
Drug: Symbiotic nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic nutritional supplement (daily mixture of symbiotics, omega-3/6 fatty acids, and amino acids)
Trial: 33858395
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual Control (CTRL)
Trial: 34803132
Drug: Monthly anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly anti-VEGF injections
Trial: 39675824
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg/day)
Trial: 32990938
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (PCA) with fentanyl
Trial: 36335783
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg QD (arm A)
Trial: 32069126
Drug: Etonogestrel-releasing subdermal
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etonogestrel-releasing subdermal implant
Trial: 32069126
Drug: 52-mg levonorgestrel-releasing
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 52-mg levonorgestrel-releasing intrauterine system
Trial: 36371675
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia (sevoflurane maintenance)
Trial: 35412685
Drug: N. sativa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. sativa oil (two capsules of 500 mg)
Trial: 35412685
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules of 500 mg mineral oil)
Trial: 34314574
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg/day for creatinine clearance ≥50 ml/min; 7.5 mg/day for ≥30-<50 ml/min)
Trial: 39264503
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of rosuvastatin
Trial: 32629662
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract tablets
Trial: 32930627
Drug: TCHMC 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCHMC 200 g per day
Trial: 32930627
Drug: TCHMC 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCHMC 300 g per day
Trial: 32930627
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 g TCHMC per day)
Trial: 34244277
Drug: Guided self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-help intervention (EG) based on Acceptance and Commitment Therapy (ACT), comprising an introduction and seven modules (one module per week, processing time about 45-60 min).
Trial: 32184007
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia alone (G group)
Trial: 33615395
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 0.15 mg Se/kg (NS-Gly)
Trial: 33615395
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 0.60 mg Se/kg (NS-Gly)
Trial: 33615395
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 0.30 mg Se/kg (Na2SeO3)
Trial: 33615395
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet (control, 0.13 mg Se/kg)
Trial: 33615395
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 0.30 mg Se/kg (NS-Gly)
Trial: 33615395
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet + 0.45 mg Se/kg (NS-Gly)
Trial: 33142505
Drug: Natural astaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural astaxanthin (ASTA) 25 mg/kg
Trial: 33142505
Drug: Natural astaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural astaxanthin (ASTA) 50 mg/kg
Trial: 33142505
Drug: Natural astaxanthin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural astaxanthin (ASTA) 100 mg/kg
Trial: 33142505
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg/kg ASTA)
Trial: 36129031
Drug: Methohexital (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexital (0.5 mg/kg)
Trial: 32557166
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose CT (ULDCT)
Trial: 35221758
Drug: Dexmedetomidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.0 μg/kg
Trial: 32759621
Drug: Rectal ulcers
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rectal ulcers >2 cm
Trial: 32759621
Drug: Deep rectal
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep rectal ulcers >2 cm
Trial: 33722073
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy plus fluoxetine
Trial: 33722073
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy plus placebo
Trial: 34461078
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (enoxaparin; 40 mg subcutaneously)
Trial: 34461078
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no low-molecular-weight heparin)
Trial: 32049831
Drug: pyridostigmine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyridostigmine 0.2 mg/kg plus glycopyrrolate 0.01 mg/kg
Trial: 33296560
Drug: Paclitaxel-coated devices
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-coated devices (drug-coated-device group)
Trial: 39215323
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg)
Trial: 32812663
Drug: Cream containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream containing niosomes loaded with 1% w/v purple glutinous rice extract
Trial: 34166648
Drug: 52 mg
RxNorm normalized name: papain 52 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52 mg levonorgestrel intrauterine system (IUS)
Trial: 35027169
Drug: High-Flow Nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Flow Nasal Oxygen (70 L min−1)
Trial: 35027169
Drug: Facemask Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facemask Oxygen (15 L min−1)
Trial: 33688840
Drug: Online mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online mindfulness-based cognitive behavioral therapy (CBT-M) combined with standard psychiatric care (n=22)
Trial: 33944622
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) at a starting dose of 0.5 mg/kg/day, titrated to 1.2 mg/kg/day
Trial: 34744060
Drug: Mg-Ca alloy
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Allay]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-Ca alloy scaffold
Trial: 34744060
Drug: Mg-Sr alloy
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Allay]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-Sr alloy scaffold
Trial: 34158437
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and Root Planing and Punica granatum gel
Trial: 34647849
Drug: chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy alone
Trial: 35177053
Drug: Dapagliflozin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin as an add-on therapy to standard of care (SoC)
Trial: 33961534
Drug: Red light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red light LED therapy 2–3 times/week for 6 weeks
Trial: 33961534
Drug: Red light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red light LED therapy
Trial: 33293656
Drug: Highly Active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly Active Antiretroviral Treatment (HAART)
Trial: 33261620
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all beneficial strategies